Trial
NCT06876142
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Multiple Myeloma
Intervention
Mirdametinib
Why stopped
Administrative hold pending non-safety related changes to the study design.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-02